Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Several ribosomopathies share features such as inherited bone marrow failure, which is characterized a reduced number of blood cells and by a predisposition to cancer. Other features can include skeletal abnormalities and growth retardation. However, clinically these diseases are distinct, and do not show a consistent set of features.
On February 10, 2025, the AIDS Vaccine Advocacy Coalition and the Journalism Development Network filed suit in the U.S. District Court for the District of Columbia, seeking a preliminary injunction that would prevent the enforcement of Executive Order 14169, along with an order reinstating foreign assistance funding. On February 13, 2025, U.S. district court Judge Amir Ali granted a temporary restraining order (TRO) and told the government to pay $2 billion in funds that were owed to aid agencies. The government did not comply, leading the plaintiffs to return to court to seek enforcement, and Judge Ali gave the government until February 26 to comply. The Trump administration appealed that ruling to the U.S. Court of Appeals for the District of Columbia, also requesting a stay pending appeal; the stay was rejected. The administration then appealed to the U.S. Supreme Court, asking the court to vacate the TRO and grant the stay while the appeal proceeded in the appeals court. On March 5, 2025, the United States Supreme Court ruled 5-4 that the federal government must pay for projects already completed. Voting in the majority were the 3 Democratic appointees, Chief Justice Roberts, and Justice Barrett; voting in the minority were the other 4 Republican appointees. However, Federal Judge Ali was ordered to proceed with "due regard for the feasibility of any compliance timelines." On March 6, Judge Ali ruled that at least some payments for completed work must be made by March 10.
The Bradford assay uses the spectral properties of Coomassie brilliant blue G-250 to estimate the amount of protein in a solution. A protein sample is added to a solution of the dye in phosphoric acid and ethanol. Under the acid conditions the dye is normally a brownish colour but on binding to the protein the blue form of the dye is produced. The optical absorbance of the solution is measured at a wavelength of 595 nm. The dye is noted for its high level of sensitivity: 5 μg of protein can be detected. However, among the disadvantages of the method is its variability of color development with different proteins: the absorbance change per unit mass of proteins varies with the type of the protein. On binding to a protein, the negatively charged Coomassie brilliant blue G-250 dye molecule will give an overall negative charge to the protein. This property can be used to separate proteins or protein complexes using polyacrylamide gel electrophoresis under non-denaturing conditions in a technique called blue native PAGE. The mobility of the complex in the polyacrylamide gel will depend on both the size of the protein complex (i.e., the molecular weight) and the amount of dye bound to the protein. Coomassie blue staining can also be used as a loading control staining method in western blot analysis. It is applied as an anionic pre-antibody stain.
Christian René Marie Joseph, Viscount de Duve (2 October 1917 – 4 May 2013) was a Nobel Prize-winning Belgian cytologist and biochemist. He made serendipitous discoveries of two cell organelles, peroxisomes and lysosomes, for which he shared the Nobel Prize in Physiology or Medicine in 1974 with Albert Claude and George E. Palade ("for their discoveries concerning the structural and functional organization of the cell"). In addition to peroxisome and lysosome, he invented scientific names such as autophagy, endocytosis, and exocytosis on a single occasion. The son of Belgian refugees during the First World War, de Duve was born in Thames Ditton, Surrey, England. His family returned to Belgium in 1920. He was educated by the Jesuits at Our Lady College, Antwerp, and studied medicine at the Catholic University of Louvain. Upon earning his MD in 1941, he joined research in chemistry, working on insulin and its role in diabetes mellitus. His thesis earned him the highest university degree agrégation de l'enseignement supérieur (equivalent to PhD) in 1945. With his work on the purification of penicillin, he obtained an MSc degree in 1946. He went for further training under later Nobel Prize winners Hugo Theorell at the Karolinska Institutet in Stockholm, and Carl and Gerti Cori at the Washington University in St. Louis. He joined the faculty of medicine at Leuven in 1947. In 1960 he was invited to the Rockfeller Institute (now Rockefeller University).
Under the weight of this offensive, Chinese forces drove MacArthur's forces out of North Korea and captured Seoul, but were subsequently pushed back south of Pyongyang north of the 38th Parallel. The war also catalyzed the rapid modernization of the People's Liberation Army Air Force (PLAAF). In 1962, the PLA Ground Force also fought India in the Sino-Indian War. In a series of border clashes in 1967 with Indian troops, the PLA suffered heavy numerical and tactical losses. Before the Cultural Revolution, military region commanders tended to remain in their posts for long periods. The longest-serving military region commanders were Xu Shiyou in the Nanjing Military Region (1954–74), Yang Dezhi in the Jinan Military Region (1958–74), Chen Xilian in the Shenyang Military Region (1959–73), and Han Xianchu in the Fuzhou Military Region (1960–74). In May 1965 during the Cultural Revolution, PLA abandoned the use of the military ranks that it had adopted in 1955. The Central Military Commission had deemed that ranks were an expression of bourgeois right and hierarchy which led to individualist attitudes, inequality, and a sense of disunity. This was reversed in September 1988. The establishment of a professional military force equipped with modern weapons and doctrine was the last of the Four Modernizations announced by Zhou Enlai and supported by Deng Xiaoping. In keeping with Deng's mandate to reform, the PLA has demobilized millions of men and women since 1978 and has introduced modern methods in such areas as recruitment and manpower, strategy, and education and training.
Sources: en.wikipedia.org
It is then lowered by a strong rope over an outcrop of coral and the boat trawls over the coral causing it to break off and be caught in the netting. The device is then drawn to the surface by the boat crew.
== Mechanism of action == Both dalfopristin and quinupristin bind to sites located on the 50S subunit of the ribosome. Initial dalfopristin binding results in a conformational change of the ribosome, allowing for increased binding by quinupristin. A stable drug-ribosome complex is created when the two drugs are used together. This complex inhibits protein synthesis through prevention of peptide-chain formation and blocking the extrusion of newly formed peptide chains. In many cases, this leads to bacterial cell death.
Endocrine glands secrete their product into the extracellular space where it is rapidly taken up by the circulatory system. Exocrine glands secrete their products into a duct that then delivers the product to the lumen of an organ or onto the free surface of the epithelium. Their secretions include tears, saliva, oil (sebum), enzyme, digestive juices, sweat.
=== Oxides === Einsteinium(III) oxide (Es2O3) was obtained by burning einsteinium(III) nitrate. It forms colorless cubic crystals, which were first characterized from microgram samples sized about 30 nanometers. Two other phases, monoclinic and hexagonal, are known for this oxide. The formation of a certain Es2O3 phase depends on the preparation technique and sample history, and there is no clear phase diagram. Interconversions between the three phases can occur spontaneously, as a result of self-irradiation or self-heating. The hexagonal phase is isotypic with lanthanum oxide where the Es3+ ion is surrounded by a 6-coordinated group of O2− ions.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.